Related Experiment Video
Updated: Jul 18, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting stents: a pharmacoclinical perspective
1Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
The National Medical Journal of India
|November 15, 2006
Summary
Drug-eluting stents significantly reduce in-stent stenosis after coronary stenting, though their cost-effectiveness compared to bare metal stents requires further evaluation. Future innovations may involve nanotechnology for more compact devices.
Area of Science:
- Cardiovascular medicine
- Interventional cardiology
- Biomedical engineering
Background:
- Percutaneous coronary intervention (PCI) has advanced significantly, surpassing bypass surgery in frequency.
- Coronary stenting is a key PCI technique, but faces challenges like in-stent stenosis (neointimal proliferation).
Purpose of the Study:
- To review the progress and challenges in coronary stenting, particularly the role of drug-eluting stents (DES).
- To discuss the impact of DES on reducing in-stent stenosis and address pharmacoeconomic concerns.
Main Methods:
- Review of literature on coronary stenting techniques and outcomes.
- Analysis of the evolution and efficacy of drug-eluting stents.
- Discussion of clinical trial challenges and future technological advancements.
Main Results:
- Drug-eluting stents have approximately halved the incidence of in-stent stenosis compared to bare metal stents.
- Various pharmacological agents have shown varying success in coronary stents, with ongoing development.
- Significant cost disparities exist between DES and bare metal stents, raising pharmacoeconomic questions.
Conclusions:
- Drug-eluting stents represent a major advancement in reducing restenosis after coronary stenting.
- Further research is needed to optimize pharmacoeconomics and explore future technologies like nanotechnology for improved stent design.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...